Bioprinted Organotypic GBM-Cancer-On-Chip

E. Dogan, R. Schwartz, S. Karimu, A. Miri
Rowan University,
United States

Keywords: glioblastoma, cancer-on-chip, cancer, microfluidics, bioprinting


Paper Title: Bioprinted Organotypic GBM-Cancer-On-Chip Autor’s Name: Elvan Dogan, Rachel Schwartz, Shola Karimu, Amir K. Miri Affiliations: Department of Mechanical Engineering, Department of Biomedical Engineering, Rowan University, Glassboro, NJ 08033 Contact email: Abstract Glioblastoma multiforme (GBM) is a leading cause of cancer mortality in the USA, with approximately $7 billion health spending per year. The median survival rate is around 15 months for patients who are treated with chemotherapy and/or radiotherapy. Traditional culture models are unable to mimic the tumor angiogenesis and complex tumor microenvironment. Furthermore, they cannot replicate brain blood barriers (BBB) a key tumor element. Mimicking BBB is essential to capture the tissue permeability for drug diffusion, in which BBB permeability is regulated by GBM cells and astrocytes. We bioprinted a 3D organotypic model that may mimic GBM microenvironment with three types of cells interacting along with extracellular matrix clues. We have used a combination of hyaluronic acid (3-5%) and gelatin methacryloyl (5-7%) as our bioink. We encapsulated U87 cell line and astrocytes in our bioink and patterned into realistic shapes, and then seeded brain vascular endothelial cells into our channels. Upon culture circulation over seven days, we tested the biological activity of the proposed model and measured CD31 and CD34 biomarkers. In this work, we demonstrated the use of bioprinting to make tumor-on-a-chip for drug testing (Fig. 1).